- Investor's Business Daily•3 days ago
Wall Street will be keyed in Tuesday to Biogen's earnings for a first look at whether payer pushback hindered sales of Spinraza.
- Zacks•3 days ago
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.
- Barrons.com•5 days ago
Last month, I urged investors to stay away from Gilead Sciences (GILD), arguing that it had, in effect, become a value trap (even if I didn't use those exact words. Barclays analyst Geoff Meacham and team note that "investors seem increasingly more frustrated" with not only Gilead, but with Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) as well.
ALXN : Summary for Alexion Pharmaceuticals, Inc. - Yahoo Finance
Alexion Pharmaceuticals, Inc. (ALXN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||116.60 x 100|
|Ask||120.93 x 100|
|Day's Range||115.57 - 119.29|
|52 Week Range||109.12 - 159.93|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||66.38|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|